Vladimir A. Konev

Vladimir A. Konev

Auto-generated profile, based on publicly available information

Vladimir A. Konev

Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2024 in Almanac of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YIYuri D. Ivanov
Yuri D. Ivanov
ENEkaterina Nevedrova
Ekaterina Nevedrova
AVAngelina Vinogradova
Angelina Vinogradova
KGKristina Goldaeva
Kristina Goldaeva
TPTatyana Pleshakova
Tatyana Pleshakova
AAAlexander Archakov
Alexander Archakov
Rationale: Colorectal cancer (CRC) is one of the most prevalent oncological diseases with high mortality. Invasive optical (endoscopic) colono- scopy has been recognized as a golden standard for the CRC diagnostics. A promising area is the development of non-invasive tools for CRC diagnosis with circular RNA (circRNA). One of the most sensitive non-invasive tools for detection of cancer RNA markers is considered to be the biosensor methods with the use of nanowire chips with oDNA probes (fragments of DNA oligonucleotides) immobilized on their surface. It has been previously shown that circRNA hsa_circ_0136666_CBC1, hsa_circ_0031263_CBC1, and hsa_circ_0072715_CBC1 are associated with CRC. Aim: To determine the lower limit of concentration sensitivity of detection of CRC-associated circRNA with nanowire chips with immobilized oDNA probes, to demonstrate the usability of these chips for non-invasive detection of circRNA in plasma in the CRC diagnostics, and to establish the potential for the use of nanowire chips for the early CRC diagnosis. Methods: To ensure biospecific binding of the circRNA hsa_circ_0136666_CBC1, hsa_circ_0031263_CBC1, and hsa_circ_0072715_CBC1 (the CRC markers), oDNA probes with the nucleotide sequences complementary to the target circRNA have been immobilized on the nanowire surface. At the study step 1, we detected the lower concentration limit for detection of the target molecules with the use of their analogues, i.e. synthetic model oDNA with the nucleotide sequences complementary to oDNA probes. At the study step 2, we used the nanowire chips with immobilized oDNA probes to detect the circRNA in plasma of the patients with confirmed CRC. Plasma samples from non-cancer patients were used as controls. Results: The lower concentration limit for the detection of DNA analogues of the circRNA hsa_circ_0136666_CBC1, hsa_circ_0031263_CBC1, and hsa_circ_0072715_CBC1 with nanowire chips with oDNA probes was 10-16 М. The analysis of total RNA isolated from plasma of the CRC patients showed a significant increase in the signal from the sensory elements of the nanowire chip. The analysis of plasma samples from the non-cancer patients, the nanowire signal changes were non-significant indicating the absence of detectable concentrations of the circRNA in plasma of the non-cancer patients. Conclusion: We have identified the minimal detectable concentration of the circRNA hsa_circ_0136666_CBC1, hsa_circ_0031263_CBC1, and hsa_circ_0072715_CBC1, associated to the development of CRC, with nanowire chips with immobilized oDNA probes: it was 10-16 М. The experiment showed the usability of such nanowire chips for non-invasive detection of the given circRNA markers in total RNA samples isolated from plasma of CRC patients.

6 October 2021 in CHILDREN INFECTIONS
Verified
Journal Article
Open access
PDF file
OSO. V. Shamsheva
O. V. Shamsheva
EKE. O. Kochetova
E. O. Kochetova
IPI. V. Polesko
I. V. Polesko
OMO. A. Mayorova
O. A. Mayorova
VBV. V. Belyakova
V. V. Belyakova
VKV. A. Konev
V. A. Konev
Most researchers agree that the level of protective anti-HBs decreases with age after 3-fold immunization in the first year of life, which requires the introduction of a booster dose at least 5—7 years after the completed vaccination. It is necessary to continue monitoring those vaccinated against hepatitis B in the first year of life, including those from occupational risk groups.Objective: to assess the frequency and level of anti-HBs 18 or more years after the completed course of vaccination against hepatitis B according to the standard scheme in the first year of life and to identify risk groups that need revaccination.Of 116 donor students in Moscow, 18—22 years after the completed course of vaccination against hepatitis B according to the standard scheme carried out in the first year of life, in 42.3% of cases, the titer of specific antibodies was determined below the protective level (< 10 mME/ml). At the same time, the share of seronegative individuals among medical students was higher (52.8%). Of 116 donor students, in 38.8% of cases, the titer of protective antibodies was determined in low (10—100 mME/ml) and only in 13.8% — in high (100—1000 mME/ml) and in 5.2% — very high (> 1000 mME/ml) values. Markers of DNA HBV, HBsAg, and anti-HBcor were not detected in any cases. Medical students primarily need a revaccination against hepatitis B without a preliminary study of the initial titers of specific antibodies.

1 November 2025 in Measurement Techniques
Verified
Journal Article
Closed access
YIYuri D. Ivanov
Yuri D. Ivanov
KGKristina Goldaeva
Kristina Goldaeva
ENEkaterina Nevedrova
Ekaterina Nevedrova
AVAngelina Vinogradova
Angelina Vinogradova
АААлександр Аблеев
Александр Аблеев
AAAlexander Archakov
Alexander Archakov

2 October 2022 in CHILDREN INFECTIONS
Verified
Journal Article
Open access
PDF file
EKE. O. Kochetova
E. O. Kochetova
VBV. F. Balikin
V. F. Balikin
OSO. V. Shamsheva
O. V. Shamsheva
IPI. V. Polesco
I. V. Polesco
VUV. F. Uchaykin
V. F. Uchaykin
LKL. B. Kononov
L. B. Kononov
A clinical and laboratory examination of 62 children aged 10—17 years vaccinated against hepatitis B according to the standard scheme (0—1—6 months) in the first year of life strictly according to the National Calendar of preventive vaccinations in a standard dose (10 micrograms of recombinant HBsAg) with a monocomponent vaccine was carried out.The majority of children (58%) had indicators of seroconversion of HBsAg — anti-HBs-antibodies. This indicates the fact of long-lasting Grund immunity — 10—17 years after timely 3-fold immunization against hepatitis B according to the standard scheme at a standard dose (10 mcg of recombinant HBsAg in the first year of life in the absence of Wooster immunization (revaccination) in subsequent age periods, including children with a burdened premorbid background (87.1% among those observed). Since among those observed were children with invasive medical interventions (50%), the established fact reflects the protective effect of standard Grund immunization even in children at risk — with a positive parenteral history. At the same time, the total assessment of serological and molecular biological results found that after triple immunization against hepatitis B according to the standard scheme in the first year of life, out of 62 children aged 10—17 years, the proportion of seronegative was 42%. Low levels of antibodies (10—100 IU/l) were detected in 43% of cases, high (100—1000 IU/l) — in 15% of cases. No child had an antibody level exceeding >1000 IU/l. These results require the development of new approaches to immunization of children against hepatitis B with mandatory revaccination at an older age.

14 November 2025 in Izmeritel`naya Tekhnika
Verified
Journal Article
Closed access
PDF file
YIYuri D. Ivanov
Yuri D. Ivanov
KGKristina Goldaeva
Kristina Goldaeva
ENEkaterina Nevedrova
Ekaterina Nevedrova
AVAngelina Vinogradova
Angelina Vinogradova
АААлександр Аблеев
Александр Аблеев
AAAlexander Archakov
Alexander Archakov
Renal cell carcinoma is the most common form of kidney cancer (more than 90 % of all oncological pathologies of the kidney). At an early stage of development, renal cell carcinoma can be asymptomatic, and this significantly complicates its diagnosis. Commonly used methods for diagnosing renal cell carcinoma do not allow for timely detection of this disease at early stages, thus it is necessary to develop effective and non-invasive methods for its diagnosis using biological macromolecules detectable in blood – biomarkers of this type of cancer. Small nucleolar RNAs are of great interest as such biological macromolecules. In this study, a SiNW biosensor was designed and manufactured for the direct detection of small nucleolar RNA SNORA77 in the blood, associated with renal cell carcinoma. The key element of the SiNW biosensor developed is a nanowire chip based on “siliconon- insulator” structures. The chip is manufactured using a technology similar to Smart Cut, and contains an array of silicon nanowires with n-type conductivity, on whose surface DNA oligonucleotide probes are covalently immobilized. To ensure the specificity of the analysis, the nucleotide sequence of the immobilized DNA probes is complementary to the target sequence of the small nucleolar RNA SNORA77. Purified buffer solutions containing various concentrations of synthetic DNA oligonucleotides, whose sequence is similar to the target detectable sequence of SNORA77, have been analyzed. Using the SiNW biosensor developed, the detection limit of SNORA77 was determined to be approximately 10–17 M. The SiNW biosensor has allowed us to detect an elevated level of SNORA77 in a sample isolated from the blood plasma of a patient with confirmed diagnosis of renal cell carcinoma in comparison with that in a control sample isolated from the plasma of a patient with a non-oncologic disease. The results of the study will be useful for further development of early diagnostic systems for renal cell carcinoma.